|
Apr 7
|
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
|
|
Apr 4
|
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
|
|
Mar 14
|
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
|
|
Mar 11
|
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
|
|
Feb 24
|
High Growth Tech Stocks To Watch In February 2025
|
|
Feb 21
|
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?
|
|
Feb 21
|
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest
|
|
Feb 21
|
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
|
|
Feb 18
|
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January
|
|
Feb 10
|
Why Neurocrine Biosciences Stock Sank Today
|
|
Feb 10
|
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week
|
|
Sep 30
|
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
|
|
Aug 30
|
Why Neurocrine Biosciences Stock Was Tumbling This Week
|
|
Aug 29
|
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
|
|
Aug 29
|
Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
|
|
Aug 29
|
Neurocrine reports positive data from Phase II schizophrenia treatment trial
|
|
Aug 28
|
Neurocrine Plummets 19% — Does It Still Have A Shot At This 'Significant Market Opportunity?'
|
|
Aug 28
|
Neurocrine Biosciences to Participate at Investor Conferences in September
|
|
Aug 28
|
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
|
|
Aug 28
|
Neurocrine’s mixed schizophrenia data disappoint Wall Street
|